Biopharmx Corp (BPMX) Short Interest Update

Biopharmx Corp (NYSE:BPMX) saw a significant growth in short interest in the month of April. As of April 13th, there was short interest totalling 3,440,526 shares, a growth of 33.3% from the March 31st total of 2,580,087 shares. Approximately 7.3% of the company’s stock are short sold. Based on an average daily volume of 2,286,701 shares, the short-interest ratio is currently 1.5 days.

Separately, Roth Capital set a $3.00 price objective on shares of Biopharmx Corp and gave the company a “buy” rating in a research note on Thursday, February 9th.

Shares of Biopharmx Corp (NYSE:BPMX) traded up 8.9111% during mid-day trading on Friday, hitting $0.4901. 1,462,431 shares of the company were exchanged. The stock’s market cap is $33.19 million. Biopharmx Corp has a 12-month low of $0.19 and a 12-month high of $1.22. The stock’s 50-day moving average price is $0.63 and its 200 day moving average price is $0.46.

TRADEMARK VIOLATION NOTICE: This article was originally reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this article on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The correct version of this article can be accessed at

About Biopharmx Corp

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

5 Day Chart for NYSE:BPMX

Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply